 Isoray, Inc. NYSE American: ISR today announced that it has entered into a research grant agreement with the University of Cincinnati Physicians Company for a study involving the treatment of recurrent head and neck cancers. University of Cincinnati Physicians Company is the multispecialty practice group for University of Cincinnati UC College of Medicine and UC Health. The planned trial will evaluate the safety and early effectiveness of the addition of pembrolizumab Keytruda to the regimen of Cesium-131 with surgical resection. 